National Institute of Health and Medical Research

Santen Sas

Centre National De La Recherche Scientifique

Université Versailles Saint-Quentin-En-Yvelines

Roy, Pierre

Baudouin, Christophe

Elena, Pierre-Paul

Groux, Herve

Christophe Baudouin

Pierre Roy

Frederic Lallemand

Hervé Groux

Jean-Sébastien Garrigue

Frédéric Lallemand

Jean-Sebastien Garrigue

Pierre-Paul Elena

Philippe Daull

William Rostene

David Godefroy

Alexandre Denoyer

A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.

Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.

Method for increasing the intraocular pressure in an animal

The present invention relates to a compound which is an antagonist of CXCR3 or an inhibitor of the CXCR3 receptor expression for the treatment of glaucoma.

Pharmaceutical composition for use in the treatment of glaucoma

The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.

Use of prostaglandins F2Alpha and analogues for the healing of corneal and conjunctival lesions

Growing community of inventors

Paris, France

Christophe Baudouin